CG CHONDROGENE
DEAD

Serial Number

76568022

Owner

ChondroGene Limited

Attorney

Andrew S. Ehard

First Use Date

Jan 7, 2003

Filing Date

Dec 31, 2003

Add to watchlist:

No watchlists yet
View on USPTO

CG CHONDROGENE Trademark

Serial Number: 76568022 • Registration: 3656206

CG CHONDROGENE is a trademark filed by ChondroGene Limited on December 31, 2003. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

ChondroGene Limited (15 trademarks)

Unit 15-800 Petrolia Road
Toronto M3J 3K4 , CA

Entity Type: 03

GENENEWS LIMITED (25 trademarks)

2 East Beaver Creek Road, Bldg 2
Richmond Hill Ontario L4B2N3 , CA

Entity Type: 03

Trademark Details

Filing Date

December 31, 2003

Registration Date

July 21, 2009

First Use Anywhere

January 7, 2003

First Use in Commerce

January 7, 2003

Published for Opposition

October 7, 2008

Cancellation Date

February 26, 2016

Goods & Services

(Based on 44(e)) Diagnostic preparations, namely, preparations of assays, nucleic acid primers, nucleic acid probes, proteins and antibodies, and molecular arrays of biological material for medical laboratory use; Diagnostic assays and test kits containing nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies and molecular arrays of biological material, for use to diagnose, prognoses or predict diseases for clinical or medical use; Prognostic test kits containing nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies and molecular arrays of biological material, for identifying disease risk factors and responses to therapeutic treatment for clinical or medical use; diagnostic preparations, namely, preparations of assays, nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies, and molecular arrays of biological material for clinical or medical use; diagnostic preparations, namely, preparations of extracts and nucleic acids, namely, RNA and cDNA clones for clinical use

(Based on Use in Commerce) (Based on 44(e)) Diagnostic preparations, namely, preparations of extracts and nucleic acids, namely, RNA and cDNA clones for medical research and development use; (Based on on 44(e)) Diagnostic assays and test kits for use in laboratory, medical research and chemical research and development; Diagnostic assays and test kits containing nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies and molecular arrays of biological material, for use to diagnose, prognoses or predict diseases for research use; Prognostic test kits containing nucleic acid primers, nucleic acid probes, enzymes, buffers, proteins, antibodies and molecular arrays of biological material, for identifying disease risk factors and responses to therapeutic treatment for research use

(Based on 44(e)) Diagnostic services, namely, diagnosing, preventing and predicting disease, identifying disease risk factors, diagnostic testing, gene and protein testing, identifying physiological characteristics, establishing individual preventative care programs, establishing disease treatment based on gene and protein expression and/or activity; providing genomic, proteomic and gene expression profiles useful in selecting therapeutics, evaluating the efficacy and toxicity of treatments and evaluating treatment progression, prognosing disease or disease progression and identifying disease heredity risk factors

(Based on Use in Commerce) (Based on 44(e)) Research and development, validation testing, data analysis and product development in the fields of biology, systems biology, biochemistry, molecular biology and genomics; (Based on 44(e)) Research and development, validation testing, data analysis and product development in the fields of pharmacogenomics, toxicogenomics and personalized medicine; Evaluation of clinical trial progress, and drug monitoring and monitoring of patient health progression as it relates to experimental research

Filing History

CANCELLED SEC. 8 (6-YR)
Feb 26, 2016 C8..
REGISTERED-PRINCIPAL REGISTER
Jul 21, 2009 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jun 17, 2009 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 17, 2009 AITU
NOTICE OF ALLOWANCE CANCELLED
Jun 16, 2009 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Jun 16, 2009 D1BR
NOA MAILED - SOU REQUIRED FROM APPLICANT
Dec 30, 2008 NOAM
PUBLISHED FOR OPPOSITION
Oct 7, 2008 PUBO
NOTICE OF PUBLICATION
Sep 17, 2008 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 4, 2008 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 28, 2008 CNSA
EXAMINERS AMENDMENT MAILED
Aug 28, 2008 CNEA
EXAMINER'S AMENDMENT ENTERED
Aug 27, 2008 XAEC
EXAMINERS AMENDMENT -WRITTEN
Aug 27, 2008 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 14, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 13, 2008 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 13, 2008 TROA
NON-FINAL ACTION MAILED
Jun 18, 2008 CNRT
NON-FINAL ACTION WRITTEN
Jun 17, 2008 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
May 5, 2008 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Apr 28, 2008 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 11, 2008 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 10, 2008 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 8, 2008 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 8, 2008 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 8, 2008 TROA
NON-FINAL ACTION MAILED
Nov 9, 2007 CNRT
NON-FINAL ACTION WRITTEN
Nov 8, 2007 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Oct 18, 2007 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Oct 5, 2007 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 21, 2007 PREV
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 20, 2007 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 20, 2007 COAR
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 19, 2007 CNSA
AMENDMENT FROM APPLICANT ENTERED
Sep 12, 2007 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 12, 2007 CRFA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 22, 2007 ASGN
PAPER RECEIVED
Aug 6, 2007 MAIL
PRIORITY ACTION MAILED
Mar 29, 2007 CPRA
PRIORITY ACTION WRITTEN
Mar 28, 2007 CPRA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 12, 2007 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Feb 5, 2007 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 14, 2007 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 12, 2007 CNSA
AMENDMENT FROM APPLICANT ENTERED
Jan 12, 2007 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 12, 2007 CRFA
ASSIGNED TO LIE
Jan 12, 2007 ALIE
PAPER RECEIVED
Dec 11, 2006 MAIL
LETTER OF SUSPENSION MAILED
Oct 23, 2006 CNSL
SUSPENSION LETTER WRITTEN
Oct 20, 2006 CNSL
AMENDMENT FROM APPLICANT ENTERED
Oct 13, 2006 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 5, 2006 CRFA
PAPER RECEIVED
Sep 5, 2006 MAIL
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 20, 2006 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 20, 2006 REAP
INQUIRY AS TO SUSPENSION MAILED
Mar 13, 2006 CNSI
SUSPENSION INQUIRY WRITTEN
Mar 12, 2006 CNSI
LETTER OF SUSPENSION MAILED
Sep 12, 2005 CNSL
SUSPENSION LETTER WRITTEN
Sep 9, 2005 CNSL
AMENDMENT FROM APPLICANT ENTERED
Sep 9, 2005 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 16, 2005 CRFA
PAPER RECEIVED
Aug 16, 2005 MAIL
LETTER OF SUSPENSION MAILED
Mar 23, 2005 CNSL
SUSPENSION LETTER WRITTEN
Mar 23, 2005 CNSL
EXAMINERS AMENDMENT -WRITTEN
Mar 23, 2005 CNEA
LETTER OF SUSPENSION MAILED
Mar 14, 2005 CNSL
SUSPENSION LETTER WRITTEN
Mar 13, 2005 CNSL
AMENDMENT FROM APPLICANT ENTERED
Feb 23, 2005 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2005 CRFA
PAPER RECEIVED
Jan 31, 2005 MAIL
NON-FINAL ACTION MAILED
Aug 2, 2004 CNRT
ASSIGNED TO EXAMINER
Jul 20, 2004 DOCK
NEW APPLICATION ENTERED
Jan 14, 2004 NWAP